How Can We Help You?


Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Peritoneal Cancer Trials

Select Clinical Trial

Protocol Number: ImmunoGen/GOG 3045

Protocol Title: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Eligibility: Women ≥ 18 years of age with a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.  Patients must have platinum-resistant disease.

Contact Information: (910) 715-2200

Clara McLean House
Make a Donation
News & Events